CONTROVERSIA

This profile has not been translated into English yet. It is shown in French, the reference language (automatic translation tools in your browser can help). Legal statuses and counts are shown in English.

Portrait not available

Biopharmacie / troubles du sommeil / neurologie / épilepsie / oncologie

Jazz Pharmaceuticals plc

Fiche documentée couvrant 16 controverses, dont « Création de Jazz Pharmaceuticals, Inc. » et « Acquisition d’Orphan Medical ».

Your opinion of this profile

Profile No. 5180 · Updated on 25 September 2026

16Documented controversies
9Sources
0Formal charge · all time
1Conviction

§ Legal statuses reflect the documented sources as of the date shown; they replace neither court decisions nor the presumption of innocence. Counts are not a rating. Methodology

I. Documented controversies

01

20 février 2026

Nouveaux litiges de brevets contre Tris Pharma sur Xyrem/Xywav

Status not specified

Not yet available in English — French original shown.

Après des dépôts 505(b)(2) de Tris Pharma, Jazz engage deux actions de contrefaçon dans le New Jersey visant des brevets Orange Book de Xyrem et Xywav.

Legal status — source text
pending

Sources · 1

  1. [1]
    U.S. Securities and Exchange Commission / Jazz PharmaceuticalsJazz Pharmaceuticals Q2 2026 Form 10-QRegulatory filingVery high reliability

Last verified: 21 September 2026

02

2020–octobre 2025

Plaintes antitrust alléguant que les règlements de brevets Xyrem ont retardé les génériques

Status not specified

Not yet available in English — French original shown.

Des acheteurs et tiers payeurs poursuivent Jazz et plusieurs fabricants génériques, alléguant que des accords de règlement de brevets et l’utilisation du REMS ont retardé la concurrence du sodium oxybate générique.

Sources · 1

  1. [1]
    U.S. Securities and Exchange Commission / Jazz PharmaceuticalsJazz Pharmaceuticals 2025 Form 10-KRegulatory filingVery high reliability

Last verified: 21 September 2026

03

2022–octobre 2025

Litiges Jazz–Avadel autour de Lumryz et des brevets sodium oxybate

Status not specified

Not yet available in English — French original shown.

Jazz et Avadel s’opposent dans de multiples procédures concernant Lumryz, les brevets, l’Orange Book et la concurrence sur le marché des oxybates.

Sources · 2

  1. [1]
    U.S. Securities and Exchange Commission / Jazz PharmaceuticalsJazz Pharmaceuticals 2025 Form 10-KRegulatory filingVery high reliability
  2. [2]
    U.S. Securities and Exchange Commission / Jazz PharmaceuticalsJazz-Avadel Global SettlementVery high reliability

Last verified: 21 September 2026

04

7 avril 2025

Règlement collectif Xyrem de 145 M$

Status not specified

Not yet available in English — French original shown.

Jazz Pharmaceuticals Ireland conclut un accord de 145 M$ avec la classe d’acheteurs indirects de Xyrem afin de régler les demandes liées aux accords de règlement de brevets.

Sources · 1

  1. [1]
    U.S. Securities and Exchange Commission / Jazz PharmaceuticalsJazz Xyrem Antitrust Class Settlement FilingVery high reliability

Last verified: 21 September 2026

05

21 avril 2025

Acquisition de Chimerix

No legal proceedings

Not yet available in English — French original shown.

Jazz acquiert Chimerix pour environ 935 à 944 M$ en numéraire, ajoutant le programme dordaviprone/Modeyso en oncologie rare.

Legal status — source text
Not applicable

Sources · 2

  1. [1]
    Jazz PharmaceuticalsJazz Pharmaceuticals Completes Acquisition of ChimerixHigh reliability
  2. [2]
    U.S. Securities and Exchange Commission / Jazz PharmaceuticalsJazz Pharmaceuticals Q2 2026 Form 10-QRegulatory filingVery high reliability

Last verified: 21 September 2026

06

août 2025

Approbation accélérée de Modeyso

No legal proceedings

Not yet available in English — French original shown.

La FDA accorde à Modeyso une approbation accélérée pour certains gliomes diffus de la ligne médiane H3 K27M mutés en progression après traitement.

Legal status — source text
Not applicable

Sources · 1

  1. [1]
    U.S. Securities and Exchange Commission / Jazz PharmaceuticalsJazz Pharmaceuticals Q2 2026 Form 10-QRegulatory filingVery high reliability

Last verified: 21 September 2026

07

21–27 octobre 2025

Règlement global Avadel : 90 M$ versés par Jazz et licences réciproques

Status not specified

Not yet available in English — French original shown.

Jazz et Avadel règlent tous leurs litiges; Jazz verse 90 M$, renonce à certaines redevances historiques et accorde une licence mondiale sur des brevets potentiellement opposables à Lumryz, tandis qu’Avadel accorde à Jazz un covenant de non-poursuite sur Xywav/Xyrem.

Sources · 1

  1. [1]
    U.S. Securities and Exchange Commission / Jazz PharmaceuticalsJazz-Avadel Global SettlementVery high reliability

Last verified: 21 September 2026

08

octobre 2025

Clôture complète du contentieux antitrust Xyrem

Status not specified

Not yet available in English — French original shown.

Après les différents accords de classe et opt-out, Jazz indique que l’ensemble du Xyrem Antitrust Litigation est résolu en octobre 2025.

Legal status — source text
Closed

Sources · 1

  1. [1]
    U.S. Securities and Exchange Commission / Jazz PharmaceuticalsJazz Pharmaceuticals 2025 Form 10-KRegulatory filingVery high reliability

Last verified: 21 September 2026

09

2025

Dépenses 2025 de 233,5 M$ liées aux règlements antitrust Xyrem

No legal proceedings

Not yet available in English — French original shown.

Jazz enregistre 233,5 M$ de charges en 2025 liées aux règlements du contentieux antitrust Xyrem, auxquels s’ajoute le règlement Avadel de 90 M$.

Legal status — source text
Not applicable

Sources · 1

  1. [1]
    U.S. Securities and Exchange Commission / Jazz PharmaceuticalsJazz Pharmaceuticals 2025 Form 10-KRegulatory filingVery high reliability

Last verified: 21 September 2026

10

5 mai 2021

Acquisition de GW Pharmaceuticals pour environ 7,2 Md$

No legal proceedings

Not yet available in English — French original shown.

Jazz finalise l’acquisition de GW Pharmaceuticals, ajoutant notamment Epidiolex/Epidyolex et une plateforme de médicaments cannabinoïdes.

Legal status — source text
Not applicable

Sources · 1

  1. [1]
    Jazz PharmaceuticalsJazz Pharmaceuticals Completes Acquisition of GW PharmaceuticalsHigh reliability

Last verified: 21 September 2026

11

12 août 2021

Approbation de Xywav dans l’hypersomnie idiopathique

No legal proceedings

Not yet available in English — French original shown.

La FDA approuve Xywav pour l’hypersomnie idiopathique chez l’adulte, première thérapie FDA approuvée pour cette indication.

Legal status — source text
Not applicable

Sources · 1

  1. [1]
    Jazz PharmaceuticalsJazz Announces FDA Approval of Xywav for Idiopathic HypersomniaHigh reliability

Last verified: 21 September 2026

12

années 2000–2020

Développement de Xyrem sous un système REMS très encadré

No legal proceedings

Not yet available in English — French original shown.

Xyrem, forme de sodium oxybate/GHB, est distribué dans un cadre réglementaire et REMS renforcé en raison des risques d’abus, mésusage et dépression du système nerveux central.

Legal status — source text
Not applicable

Sources · 1

  1. [1]
    U.S. Securities and Exchange Commission / Jazz PharmaceuticalsJazz Pharmaceuticals 2025 Form 10-KRegulatory filingVery high reliability

Last verified: 21 September 2026

13

18 janvier 2012

Fusion Jazz–Azur et création de l’actuelle Jazz Pharmaceuticals plc

No legal proceedings

Not yet available in English — French original shown.

Les activités de Jazz Pharmaceuticals, Inc. et Azur Pharma sont combinées; Azur est renommée Jazz Pharmaceuticals plc et devient la société mère irlandaise.

Legal status — source text
Not applicable

Sources · 1

  1. [1]
    U.S. Securities and Exchange Commission / Jazz PharmaceuticalsJazz 2017 Form 10-K — Corporate HistoryRegulatory filingVery high reliability

Last verified: 21 September 2026

14

13 juillet 2007

Orphan Medical plaide coupable pour promotion illégale hors indication de Xyrem

Conviction

Not yet available in English — French original shown.

Orphan Medical, filiale de Jazz, plaide coupable de felony misbranding pour promotion de Xyrem hors indication et paie amende, restitution et autres montants dans une résolution globale de 20 M$ impliquant aussi Jazz.

Sources · 1

  1. [1]
    U.S. Department of JusticeJazz Pharmaceuticals, Inc. Agrees to Pay $20 Million to Resolve Criminal and Civil Allegations in Off-label Marketing InvestigationVery high reliability

Last verified: 21 September 2026

15

2005

Acquisition d’Orphan Medical

No legal proceedings

Not yet available in English — French original shown.

Jazz acquiert Orphan Medical, société commercialisant notamment Xyrem; cette acquisition apporte aussi un passif de conformité historique qui sera réglé en 2007.

Legal status — source text
Not applicable

Sources · 1

  1. [1]
    U.S. Department of JusticeJazz Pharmaceuticals, Inc. Agrees to Pay $20 Million to Resolve Criminal and Civil Allegations in Off-label Marketing InvestigationVery high reliability

Last verified: 21 September 2026

16

mars 2003

Création de Jazz Pharmaceuticals, Inc.

No legal proceedings

Not yet available in English — French original shown.

Le prédécesseur Jazz Pharmaceuticals, Inc. est constitué en Californie en mars 2003 puis réincorporé dans le Delaware en 2004.

Legal status — source text
Not applicable

Sources · 1

  1. [1]
    U.S. Securities and Exchange Commission / Jazz PharmaceuticalsJazz 2017 Form 10-K — Corporate HistoryRegulatory filingVery high reliability

Last verified: 21 September 2026

II. Constellation of documented links

Each link refers to an imported relation or to a documented mention in a profile. A documented mention does not, on its own, prove a personal relationship.

List of documented links
  1. Orange2 references
    • Mentioned in “Litiges Jazz–Avadel autour de Lumryz et des brevets sodium oxybate” — Jazz Pharmaceuticals plc's profile cites Orange.
    • Mentioned in “Nouveaux litiges de brevets contre Tris Pharma sur Xyrem/Xywav” — Jazz Pharmaceuticals plc's profile cites Orange.
  2. Mars1 reference
    • Mentioned in “Création de Jazz Pharmaceuticals, Inc.” — Jazz Pharmaceuticals plc's profile cites Mars.

III. Your opinion of this profile

One opinion per browser, which you can change at any time. It rates the quality of the profile, not the person.

IV. Has something changed?

A new court decision, a missing source, a mistake? Tell us what should be updated: every request is read by the editorial team.

Update request

Jazz Pharmaceuticals plc

Say which controversy is concerned and, if possible, give a source. Between 10 and 2,500 characters.

0 / 2500